Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.

Wafaa M EzzatKhalda S AmrSalwa TawfeekHassan ElbataeEman A BayomiAhmed HeibaYasser Elhosary

Published in: BMC infectious diseases (2024)

The key differentially expressed microRNAs before and after the direct-acting antiviral (DAA) regimen were connected to the dynamics of chronic HCV infection, suggesting their potential as predictive biomarkers for HCV clearance after sofosbuvir and daclatasvir therapy.

Keyphrases

hepatitis c virus
human immunodeficiency virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis c virus infection
prognostic factors
stem cells
patient reported outcomes
bone marrow
mesenchymal stem cells
smoking cessation
replacement therapy
antiretroviral therapy